- Home
- GRC vs AUPH Comparison
GRC vs AUPH Comparison
Compare GRC & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GRC | AUPH |
|---|---|---|
| Founded | 1933 | 1993 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Fluid Controls | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.1B |
| IPO Year | 1994 | 2014 |
Fundamental Metrics
Financial Performance| Metric | GRC | AUPH |
|---|---|---|
| Price | $74.88 | $17.23 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $84.33 | $18.00 |
| AVG Volume (30 Days) | 140.5K | ★ 717.5K |
| Earning Date | 10-23-2026 | 11-10-2026 |
| Dividend Yield | ★ 1.07% | N/A |
| EPS Growth | 32.03 | ★ 5075.00 |
| EPS | ★ 2.27 | 0.53 |
| Revenue | ★ $682,389,000.00 | $283,055,000.00 |
| Revenue This Year | $7.83 | $16.68 |
| Revenue Next Year | $4.49 | $17.60 |
| P/E Ratio | $53.07 | ★ $32.07 |
| Revenue Growth | 3.44 | ★ 20.38 |
| 52 Week Low | $42.31 | $11.96 |
| 52 Week High | $92.78 | $19.25 |
Technical Indicators
Market Signals| Indicator | GRC | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 53.16 | 60.71 |
| Support Level | $73.95 | $15.27 |
| Resistance Level | $79.09 | $17.80 |
| Average True Range (ATR) | 2.26 | 0.45 |
| MACD | 0.23 | 0.07 |
| Stochastic Oscillator | 85.80 | 85.10 |
Price Performance
Historical ComparisonAbout GRC Gorman-Rupp Company (The)
Gorman-Rupp Co designs, manufactures, and globally sells pumps & pump systems for use in water, wastewater, construction, dewatering, industrial, petroleum, original equipment, agriculture, fire protection, heating, ventilating & air conditioning, military, and other liquid-handling applications. It operates in one business segment, the manufacture & sale of pumps and pump systems, and generates revenue from the same. Geographically, it generates the majority of its revenue from the United States.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.